IDEXX Laboratories (IDXX) recently drew attention after releasing its 2025 Corporate Responsibility Report, which highlighted new veterinary diagnostics offerings, AI powered imaging tools, and ongoing sustainability and workforce development initiatives.

Against this backdrop of new products and sustainability efforts, IDEXX Laboratories’ recent share price performance has been more muted, with a 7 day share price return of 4.5% but a year to date decline of 15.0%. The 3 year total shareholder return of 9.7% contrasts with a weaker 5 year total shareholder return.

If IDEXX’s recent moves in diagnostics and AI tools have your attention, it can be useful to compare it with other healthcare focused AI opportunities using this screener for 41 healthcare AI stocks.

IDEXX Laboratories now trades at a modest discount to both an estimated fair value and the average analyst target after a mixed share price record. Is this a healthy margin of safety, or a sign the market sees real risks ahead?

Most Popular Narrative: 19.7% Undervalued

The most followed valuation narrative for IDEXX Laboratories places fair value at $709.14 per share, compared with the recent close of $569.77. That gap rests on detailed assumptions about how diagnostics, software and international growth could support future earnings.

Rapid adoption of innovative diagnostic platforms such as inVue Dx, Catalyst Cortisol, and Cancer Dx are expanding IDEXX's addressable market and boosting recurring consumables demand, which is likely to drive sustained revenue and margin growth as new product usage ramps and menu breadth increases.

Read the complete narrative. Read the complete narrative.

Want to understand why this valuation stretches beyond current earnings? The narrative leans heavily on recurring diagnostics, firm margin assumptions and a premium earnings multiple. Are you curious which specific growth and profitability targets need to hold for that fair value to stack up?

Result: Fair Value of $709.14 (UNDERVALUED)

However, IDEXX Laboratories still faces pressure if veterinary visit growth remains soft or if competitors win share with lower cost diagnostics, which could challenge those bullish margin expectations.

Another View On IDEXX Laboratories Valuation

The popular narrative frames IDEXX Laboratories as roughly 19.7% undervalued, yet the market is currently charging a rich P/E of 41x. That compares with 29.1x for the broader US Medical Equipment industry, 29x for peers, and a fair ratio estimate of 30.5x.

If sentiment shifts toward that fair ratio or closer to industry and peer levels, a lot of today’s optimism appears to be reflected in the price. The question for you is whether IDEXX’s quality and growth profile justify keeping that premium, or whether valuation risk matters more at this stage.

Next Steps

If this mix of optimism and caution around IDEXX Laboratories leaves you unsure, it makes sense to review the numbers yourself and move quickly to form your own take using the 4 key rewards and 1 important warning sign.

Looking for more investment ideas beyond IDEXX Laboratories?

If IDEXX Laboratories has sharpened your focus, do not stop here. Broader idea hunting with quality screeners can turn today’s curiosity into tomorrow’s well researched watchlist.

• Target stronger value potential by reviewing companies that screen well on fundamentals and pricing through the 48 high quality undervalued stocks.
• Prioritize resilience and sleep easier at night by checking out the 85 resilient stocks with low risk scores.
• Spot under followed opportunities before they hit the spotlight by scanning the screener containing 21 high quality undiscovered gems.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.